STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
Phase I/II Clinical Trial
A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)